

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701

RECEIVED

DEC 0 4 2001

October 29, 2001 TECH CENTER 1600/2900

OP #46.

HOUSTON
WASHINGTON, D.C
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Comprissioner for Patents, Washington, DC 20231, on the date

below: October 29, 2001

Date

Steven L. Highlander

Commissioner for Patents Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC

BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client

Reference: URIF:MO-49)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven I.) Highlander Reg. No. 37,642

SLH/cmb

Encl: as noted

25087512.1

**PATENT** 

IN TI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Process incation of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN

ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 26231 for the date

below:

October 29, 2001

Date

keyen ). Highlander

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

October 29, 2001

Form PTO-1449 (modified)				1 *	Atty. Docket No.		Serial No.	
tist of Patents and Publications for Applicant's				Applicant	IOWA:031US/SLH 09/872,852 Applicant Paul B. McCray, Jr., et al.			
3 2001	INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)			_	Filing Date:		Group:	
S.S. Patent Documents Foreign			n Patent Docume	June 1, 2001 Patent Documents		Other Art		
ABL	See 1	Page 1		See Page 1		S	ee Page 1	
			U.S. Pat	tent Docum	nents			
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
			Foreign P	atent Docu	ıments	1		
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No	
		1		<del></del>		<del>                                     </del>		
	Other	Art (Includi	ng Autho	r Title Det	Dontin			
Exam.	Ref.	Art (Includi	ng Autho	r, Title, Dat		ent Paç	ges, Etc.)	
		Gallo, et al., "Ar	ntimicrobial per	Citati	on			
Exam.	Ref. Des.	Gallo, et al., "Ar Dermatol, 111(5	ntimicrobial pep	Citati otides: an emergin 3.	on g concept in	cutaneous b	iology," J. Invest	
Exam.	Ref. Des.	Gallo, et al., "Ar Dermatol, 111(5 Ganz and Lehrer 1998. Hamil et al., "HI	ntimicrobial pep ):739-743, 1998 r, "Antimicrobia E2β and HE2γ,	Citati  ptides: an emerging  3.  al peptides of verte  new members of a	g concept in debrates," Cur	cutaneous bi	iology," J. Invest  ns Immun, 10:41-4	
Exam.	Ref. Des. C1	Gallo, et al., "Ar Dermatol, 111(5) Ganz and Lehrer 1998. Hamil et al., "Hi regulated protein Harder et al., "Sl	ntimicrobial pep ():739-743, 1998 (r, "Antimicrobia E2β and HE2γ, this in the human,	Citation of the control of the contr	g concept in or ebrates," Cur on epididymis 141(3): 1245	cutaneous bi	iology," J. Invest  ns Immun, 10:41-4  mily of androgen- ).  an β-Defensin-2	
Exam.	Ref. Des. C1 C2	Gallo, et al., "Ar Dermatol, 111(5) Ganz and Lehrer 1998. Hamil et al., "Hi regulated protein Harder et al., "SI (DEFB2) to chro	ntimicrobial pep ():739-743, 1998 (r, "Antimicrobia E2β and HE2γ, as in the human, thort communicationsome region very of new hur	Citation of the control of the contr	g concept in of the gene enteromics, 46:4	cutaneous bi rent Opinion s-specific fai 1-1253, 2000 coding huma 72-475, 199	iology," J. Invest  ns Immun, 10:41-4  mily of androgen- ).  an β-Defensin-2 7.	
Exam.	Ref. Des. C1 C2 C3 C4	Gallo, et al., "Ar Dermatol, 111(5) Ganz and Lehrer 1998. Hamil et al., "Hi regulated protein (DEFB2) to chrous Jia et al., "Discor 263:211-218, 200	ntimicrobial pep (1):739-743, 1998, r., "Antimicrobia E2β and HE2γ, as in the human, thort communicationsome region of new hur 01.	Citation of tides: an emerging an emerging an emerging an emerging and peptides of vertex emergence of a man β-defensins unan β-defension una	g concept in a character," Cur on epididymis 141(3): 1245 f the gene encomics, 46:4' sing a genome	rent Opinion s-specific far s-1253, 2000 coding hum 72-475, 199	iology," J. Invest  ns Immun, 10:41-4  mily of androgen- ).  an β-Defensin-2 7.  pproach," Gene,	
Exam.	Ref. Des. C1 C2 C3 C4 C5	Gallo, et al., "Ar Dermatol, 111(5) Ganz and Lehrer 1998. Hamil et al., "Hi regulated protein Harder et al., "SI (DEFB2) to chro Jia et al., "Discor 263:211-218, 200 Kirchhoff et al., cultures," Mol. R Krull et al., "Reg	entimicrobial per 1):739-743, 1998, and HE2γ, as in the human, thort communications are gion of new hur of the communication of the co	Citation of tides: an emerging 3.  If peptides of verter of a mew members	g concept in or epididymis 141(3): 1245 If the gene encomics, 46:4' sing a genomedatogens and	cutaneous bi rent Opinion s-specific far i-1253, 2000 coding huma 72-475, 199 nics-based ap temperature	mily of androgen- ns Immun, 10:41-4 mily of androgen- n. an β-Defensin-2 7. pproach," Gene, e in epididymal ce	

25066728.1

**EXAMINER: DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Atty. Docket No.	Serial No.	
IOWA:031US/SLH	09/872,852	
s Applicant		
	t al.	
Filing Date:	Group:	
June 1, 2001	1646	
gn Patent Documents	Other Art	
See Page 1	See Page 1	
	s Applicant Paul B. McCray, Jr., e  Filing Date: June 1, 2001  ign Patent Documents	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Mathews et al., "Production of $\beta$ -defensin antimicrobial peptides by the oral mucosa and slivary glands," Infect Immun., 67(6):2740-2745, 1999.
	C10	Nilsson et al., "Patient education for adults with chronic eczema," Dermatol Nurs, 11(2):117-122, 1999.
	C11	Oren and Shai, "Mode of action of linear amphipathic α-helical antimicrobial peptides," <i>Biopolymers</i> , 47:451-463, 1998.
_	C12	Osterhoff et al., "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," Biol Reprod, 50:516-525, 1994.
	C13	Russell et al., "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," Infect Immun., 64(5):1565-1568, 1996.
	Ç14	Singh et al., "Production of β-defensins by human airway epithelia," Proc. Natl. Acad. Sci USA., 95:14961-14966, 1998.

25066728.1

Examiner:

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.